Preclinical evaluation of 188 Re-HYNIC-PSMA as a novel therapeutic agent

Journal of Radioanalytical and Nuclear Chemistry - In this study, optimized preparation, quality control, cell assessments and biostribution of 188Re-HYNIC-PSMA in normal rats and tumor bearing...     

Production and evaluation of a 67Ga-labeled anti-Ror1 monoclonal antibody in a mouse model of breast cancer

Journal of Radioanalytical and Nuclear Chemistry - Receptor tyrosine kinase Ror1 is widely expressed during embryogenesis but it is absent within most mature tissues. However, expression of Ror1...     

Development of cost effective method for production of 64Cu from natNi

A ^natNi foil was used for the production of ⁶⁴Cu via ⁶⁴Ni(p,n)⁶⁴Cu nuclear reaction when the necessary investment for target material (350 mg) is 50 times less using the ^natNi instead of ⁶⁴Ni. The produced 32.2 ± 1.8 MBq of “no carrier added” ⁶⁴Cu is sufficient for 10 mice trials on small animal PET. The radionuclide contamination was <13 ± 12 kBq for ⁵⁵Co and 4 ± 2 kBq for ⁵⁷Ni comparing to minimum detectable activity and only 52 ± 2 kBq of ⁶¹Cu was in ⁶⁴Cu due to the modified ion exchange separation. The concentration of Fe(III) was maintained under 1.7 ppm by precipitation and filtering of Fe(OH)₃ due to the chemical purity was required.     

Experimental study and nuclear model calculation for 65Zn production

Excitation functions and theoretical yields via charge particle induced reactions were evaluated using EMPIRE-3.2.2 and ALICE/ASH codes and the obtained results have been discussed and compared with the available reported experimental data. It has been verified that ^natCu(p,n)⁶⁵Zn reaction is the optimum ⁶⁵Zn production route. The ⁶⁵Zn was produced using ^natCu(p,xn) ⁶⁵Zn reaction in the energy range of 16.8 → 12.2 MeV with the thick target yield of 0.15 ± 0.005 MBq/μA h. The ⁶⁵Zn radionuclide was purified by anion exchange chromatography.

     

Optimized preparation and preliminary evaluation of [64Cu]–DOTA–trastuzumab for targeting ErbB2/Neu expression

Breast cancer radioimmunoscintigraphy targeting HER2/neu expression is a growing field of work in nuclear medicine research. Trastuzumab is a monoclonal antibody that binds with high affinity to HER2/neu, which is over expressed on breast and other tumors. Developing new tracers for the detection of this cancer is of great interest. In this study, trastuzumab was successively labeled with [⁶⁴Cu]CuCl₂ after conjugation with DOTA-NHS-ester. The conjugate was purified by molecular filtration, the average number of DOTA conjugated per mAb was calculated and total concentration was determined by spectrophotometric method. DOTA–trastuzumab was labeled with ⁶⁴Cu produced by ⁶⁸Zn(p,αn)⁶⁴Cu nuclear reaction (30 MeV protons at 180 μA). Radiochemical purity, integrity of protein after radiolabeling and immunoreactivity of radiolabeled mAb trastuzumab with HER2/neu antigen and SkBr3 cell line were performed by RIA. In vitro stability of radiolabeled mAb in human serum was determined by thin layer chromatography. In vitro internalization studies were performed with the SkBr3 cell line and the tissue biodistribution of the ⁶⁴Cu–DOTA–trastuzumab was evaluated in wild-type rat (90 ± 5.5 μCi, 2, 6, 12, 24 h p.i.). The radioimmunoconjugate was prepared with a radiochemical purity of higher than 96 ± 0.5 % (ITLC) and specific activity as high as 5.3 μCi/μg. The average number of chelators per antibody for the conjugate used in this study was 5.8/1. The sample was showed to have similar patterns of migration in the gel electrophoresis. The ⁶⁴Cu–DOTA–trastuzumab showed high immunoreactivity towards HER2/neu antigen and SkBr3 cell line. In vitro stability of the labeled product was found to be more than 94 % in PBS and 82 ± 0.5 % in human serum over 48 h. In vitro internalization studies of the ⁶⁴Cu–DOTA–trastuzumab showed that up to 11.5 % of the radioimmunoconjugate internalized after 10 h. The accumulation of the radiolabeled mAb in liver, skin, intestine, lung, spleen, kidney and other tissues demonstrates a similar pattern to the other radiolabeled anti-HER2 immunoconjugates. ⁶⁴Cu–DOTA–trastuzumab is a potential compound for molecular imaging of PET for diagnosis and treatment studies and follow-up of HER2 expression in oncology.